Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to…
BOSTON and JERUSALEM, June 28, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a conference call to discuss results…